Shunt dysfunction and mortality after transjugular intrahepatic portosystemic shunt (TIPS) in patients with portal hypertension

被引:2
|
作者
Buettner, Laura [1 ,2 ,3 ]
Pick, Lisa [1 ,2 ,3 ]
Jonczyk, Martin [1 ,2 ,3 ]
Fehrenbach, Uli [1 ,2 ,3 ]
Collettini, Federico [1 ,2 ,3 ,4 ]
Auer, Timo Alexander [1 ,2 ,3 ,4 ]
Schnapauff, Dirk [1 ,2 ,3 ]
De Bucourt, Maximilian [1 ,2 ,3 ]
Wieners, Gero [1 ,2 ,3 ]
Gebauer, Bernhard [1 ,2 ,3 ]
Aigner, Annette [1 ,2 ,3 ,5 ]
Boening, Georg [1 ,2 ,3 ]
机构
[1] Charite Univ Med Berlin, Charitepl 1, D-10117 Berlin, Germany
[2] Free Univ Berlin, Charitepl 1, D-10117 Berlin, Germany
[3] Humboldt Univ, Dept Radiol, Charitepl 1, D-10117 Berlin, Germany
[4] Charite Univ Med Berlin, Berlin Inst Hlth, Charitepl 1, D-10117 Berlin, Germany
[5] Humboldt Univ, Inst Biometry & Clin, Charitepl 1, D-10117 Berlin, Germany
来源
INSIGHTS INTO IMAGING | 2024年 / 15卷 / 01期
关键词
Transjugular intrahepatic portosystemic shunt; Transjugular intrahepatic portosystemic shunt dysfunction; Stent thrombosis; Stent stenosis; Mortality; REFRACTORY ASCITES; UNCOVERED STENTS; SURVIVAL; CIRRHOSIS; PATENCY; POLYTETRAFLUOROETHYLENE; SCORE;
D O I
10.1186/s13244-024-01768-8
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
ObjectivesTransjugular intrahepatic portosystemic shunt (TIPS) is a catheter-based, minimally invasive procedure to reduce portal hypertension. The aim of the study was to investigate dysfunction and mortality after TIPS and to identify factors associated with these events.MethodsA retrospective analysis of 834 patients undergoing TIPS implantation in a single center from 1993-2018 was performed. Cumulative incidence curves were estimated, and frailty models were used to assess associations between potentially influential variables and time to dysfunction or death.Results1-, 2-, and 5-year mortality rates were 20.9% (confidence interval (CI) 17.7-24.1), 22.5% (CI 19.1-25.8), and 25.0% (CI: 21.1-28.8), 1-year, 2-year, and 5-year dysfunction rates were 28.4% (CI 24.6-32.3), 38.9% (CI 34.5-43.3), and 52.4% (CI 47.2-57.6). The use of covered stents is a protective factor regarding TIPS dysfunction (hazard ratio (HR) 0.47, CI 0.33-0.68) but does not play a major role in survival (HR 0.95, CI 0.58-1.56). Risk factors for mortality are rather TIPS in an emergency setting (HR 2.78, CI 1.19-6.50), a previous TIPS dysfunction (HR 2.43, CI 1.28-4.62), and an increased Freiburg score (HR 1.45, CI 0.93-2.28).ConclusionThe use of covered stents is an important protective factor regarding TIPS dysfunction. Whereas previous TIPS dysfunction, emergency TIPS implantation, and an elevated Freiburg score are associated with increased mortality. Awareness of risk factors could contribute to a better selection of patients who may benefit from a TIPS procedure and improve clinical follow-up with regard to early detection of thrombosis/stenosis.Critical relevance statementThe use of covered stents reduces the risk of dysfunction after transjugular intrahepatic portosystemic shunt (TIPS). TIPS dysfunction, emergency TIPS placement, and a high Freiburg score are linked to higher mortality rates in TIPS patients.Key PointsThe risk of dysfunction is higher for uncovered stents compared to covered stents.Transjugular intrahepatic portosystemic shunt dysfunction increases the risk of instantaneous death after the intervention.A higher Freiburg score increases the rate of death after the intervention.Transjugular intrahepatic portosystemic shunt implantations in emergency settings reduce survival rates.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] THE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) IN THE TREATMENT OF PORTAL-HYPERTENSION
    MCCORMICK, PA
    DICK, R
    BURROUGHS, AK
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1994, 8 (03) : 273 - 282
  • [2] Transjugular Intrahepatic Portosystemic Shunt (tips) In Chylothorax Due To Portal Hypertension
    Cagnina, R. E.
    Enfield, K. B.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [3] Pulmonary hypertension after transjugular intrahepatic portosystemic shunt (TIPS)
    vanderHeijde, RMJL
    Lameris, JS
    vandenBerg, B
    Wagenvoort, CA
    Hilvering, C
    vanBuuren, HR
    EUROPEAN RESPIRATORY JOURNAL, 1996, 9 (07) : 1562 - 1564
  • [4] SHUNT PATENCY AFTER TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS)
    BENNER, K
    SAHAGUN, G
    MEYER, RA
    BARTON, RE
    KELLER, FS
    RABKIN, J
    ROSCH, J
    GASTROENTEROLOGY, 1993, 104 (04) : A876 - A876
  • [5] DIASTOLIC DYSFUNCTION PREDICTS MORTALITY AFTER TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) CREATION
    Lang, G.
    Banerjee, S.
    Van Ha, T.
    Reau, N.
    Te, H.
    Jensen, D.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S73 - S73
  • [6] A novel indication for transjugular intrahepatic portosystemic shunt (TIPS): Portal hypertension enteropathy
    Harmon, Kimberly S.
    McCashland, Timothy M.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S354 - S354
  • [7] Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension
    Barange, K
    Rousseau, H
    Vinel, JP
    PRESSE MEDICALE, 1997, 26 (24): : 1162 - 1167
  • [8] Transjugular intrahepatic portosystemic shunting (TIPS): A shunt is a shunt is a shunt!
    Saksena, S
    Elias, E
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1997, 9 (01) : 3 - 5
  • [9] The transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension
    Hassoun, Z
    Pomier-Layrargues, G
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2004, 16 (01) : 1 - 4
  • [10] The transjugular intrahepatic portosystemic shunt (TIPS)
    Peck-Radosavljevic, M
    Pidlich, J
    WIENER KLINISCHE WOCHENSCHRIFT, 2000, 112 (22) : 947 - 954